International Stem Cell Corporation Provides Update on the Status of Its Parkinson's Disease Program

The program continues to progress on the plan developed with input from the FDA. To date no adverse events or pathological reactions have been observed in any of the completed preclinical pharmacology/toxicology studies.

http://ift.tt/1vxofno